News & Events
October 12, 2017
Spiral Therapeutics Receives Positive IND Submission Guidance from FDA

Spiral Therapeutics, Inc., a biopharmaceutical company developing first-in-class therapies targeting inner ear disorders, reported positive feedback from the US Food and Drug Administration (FDA) in response to Spiral’s first pre-Investigational New Drug (pre-IND) package submission.

 

Share: